Search the Newsreel

Mineralys Therapeutics Inc (MLYS) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Mineralys Therapeutics Inc (MLYS). It lists several major institutional shareholders and their shareholdings, highlighting changes in their positions. Key firms like Catalys Pacific, RA Capital Management, and Fidelity Management & Research Company LLC are …

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring an 80% Upside Potential in the Biotech Arena

Mineralys Therapeutics, Inc. (MLYS) is highlighted as a compelling biotech investment opportunity due to its focus on developing medicines for diseases like hypertension and chronic kidney disease, particularly its lead product lorundrostat. Analysts project an 80.08% upside potential, with 9 out of 10 ratings …

New Mineralys hires receive stock awards vesting over four years

Mineralys Therapeutics granted inducement stock awards to two new non-executive employees, comprising stock options for 42,800 shares and restricted stock units for 32,100 shares. These awards, approved by the Compensation Committee on July 17 and July 20, 2026, are part of the company's 2025 …

Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Mineralys Therapeutics Inc (MLYS), providing a breakdown of major shareholders, their proportions, and evolving institutional holdings. It lists top individual institutional investors like Catalys Pacific, LLC and RA Capital Management, LP, and categorizes shareholder types such as …

Troluce Capital Advisors LLC Takes Position in Mineralys Therapeutics, Inc. $MLYS

Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Mineralys Therapeutics Inc (MLYS), though it notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows current stock information including the market …

Mineralys Therapeutics Inc (MLYS) Cash Flow

This article presents the detailed quarterly and annual cash flow statements for Mineralys Therapeutics Inc (MLYS), covering operating, investing, and financing activities. It provides financial figures for various cash flow components from FY2021Q4 to FY2026Q1, along with year-over-year percentage changes. The article also includes …

Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend history of Mineralys Therapeutics Inc (MLYS). It states that the company has distributed $0.00 in dividends over the past five years, indicating no recorded dividend payouts. The information includes the current stock price and market capitalization for …

Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common shares

Mineralys Therapeutics Chief Commercial Officer Eric Warren sold 7,438 shares on July 21, 2026, for $26.87 per share after exercising stock options. Following these transactions, his direct holdings decreased to 38,400 shares, with 245,438 stock options remaining outstanding. The total value disposed of was …

Form 4 Mineralys Therapeutics Inc For: 23 July By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Mineralys Therapeutics Inc. dated July 23. It indicates that the document is published by Reuters and includes the stock symbol MLYS, showing a slight negative performance of -1.07%. The main …

Mineralys Therapeutics CCO Eric Warren sells $199k in shares

Eric Warren, Chief Commercial Officer at Mineralys Therapeutics (NASDAQ: MLYS), sold 7,438 shares of the company's common stock for $199,885 after acquiring an equal number of shares through stock options. This transaction was part of a Rule 10b5-1 selling plan. The company recently priced …

Mineralys (NASDAQ: MLYS) CCO sells 7,438 shares after option exercise

Mineralys Therapeutics' Chief Commercial Officer, Eric Warren, exercised 7,438 stock options at $13.24 per share and subsequently sold all 7,438 common shares at a weighted-average price of $26.8735. These transactions, which occurred on July 21, 2026, were executed under a Rule 10b5-1 plan adopted …

Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise

An affiliate of Mineralys Therapeutics (MLYS) has filed a Form 144 notice for the potential sale of 7,438 shares of common stock. This sale, valued at $199,884.80, is scheduled for July 21, 2026, following the exercise of employee stock options via a broker-assisted cashless …

Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares By Investing.com

Mineralys Therapeutics CMO David Rodman sold 416 shares for $11,036 while simultaneously acquiring the same number of shares by exercising stock options for $6,423 under a pre-arranged trading plan. Post-transaction, Rodman holds 51,384 shares and 3,334 stock options. The company's stock has seen a …

Form 144 Mineralys Therapeutics For: 17 July By Investing.com

This article from Investing.com is a brief notice about a Form 144 filing for Mineralys Therapeutics (MLYS) on July 17. Form 144 is an SEC filing that indicates an intent to sell restricted securities. The article provides minimal detail beyond this announcement.

Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise

Mineralys Therapeutics (MLYS) insider David Rodman has scheduled a sale of 416 common shares on July 17, 2026, following the exercise of employee stock options via a cashless exercise through Merrill Lynch. This notice also details several prior share sales by Rodman between April …

Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Mineralys Therapeutics (MLYS) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, detailing updates on their lead drug, lorundrostat. Key topics included the submission of an NDA with a December 6 PDUFA date, strategic financial moves such as acquiring full IP rights for …

Mineralys Therapeutics (MLYS) Q3 2025 earnings summary

Mineralys Therapeutics (MLYS) reported its Q3 2025 earnings, highlighting plans for NDA submission of lorundrostat by early 2026 following positive FDA feedback. The company's cash position of $593.6 million is expected to fund operations into 2028, with significant public equity financings in 2025 contributing …

Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton sold 10,700 shares on July 13, 2026, reducing his total holdings to 603,621 shares. This transaction is part of a trend of more insider selling than buying at the company over the past year. Shares were trading …

Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com

This article reports on a Form 4 filing for Mineralys Therapeutics Inc. for July 15. The brief piece includes the company's stock symbol (MLYS) and a minor percentage change. The content primarily lists market data for various indices, commodities, bonds, and shares.

Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock

Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of company stock, valued at $291,441, on July 13, 2026, as part of a pre-planned trading arrangement. Following this sale, Congleton still owns 603,621 shares. The company's stock has seen a significant return over the past …

Mineralys therapeutics CMO Rodman sells $556,671 in shares

Mineralys Therapeutics' Chief Medical Officer, Rodman David Malcom, sold company shares totaling $556,671 across two transactions in July 2026, executed under a pre-arranged trading plan. Concurrently, he acquired shares worth $102,365 through stock option exercises. The company recently undertook a public offering and secured …

Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options

Mineralys Therapeutics (MLYS) Chief Medical Officer David Malcom Rodman sold 20,407 common shares and exercised options for 14,058 common shares on July 13 and 15, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these sales, …

Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan

Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares of common stock on July 13, 2026, at a weighted-average price of $27.2375 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in January 2025. Following the sale, Congleton directly holds …

Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS)

An insider at Mineralys Therapeutics (NASDAQ: MLYS), David Rodman, plans to sell 6,349 shares of common stock through Merrill Lynch on July 15, 2026, with an aggregate market value of approximately $168,954.55. These shares were acquired via an exercise of employee stock options on …